361 related articles for article (PubMed ID: 21849452)
1. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals.
Tomaras GD; Binley JM; Gray ES; Crooks ET; Osawa K; Moore PL; Tumba N; Tong T; Shen X; Yates NL; Decker J; Wibmer CK; Gao F; Alam SM; Easterbrook P; Abdool Karim S; Kamanga G; Crump JA; Cohen M; Shaw GM; Mascola JR; Haynes BF; Montefiori DC; Morris L
J Virol; 2011 Nov; 85(21):11502-19. PubMed ID: 21849452
[TBL] [Abstract][Full Text] [Related]
2. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
3. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
[TBL] [Abstract][Full Text] [Related]
5. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.
Walker LM; Simek MD; Priddy F; Gach JS; Wagner D; Zwick MB; Phogat SK; Poignard P; Burton DR
PLoS Pathog; 2010 Aug; 6(8):e1001028. PubMed ID: 20700449
[TBL] [Abstract][Full Text] [Related]
6. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.
Li Y; Svehla K; Louder MK; Wycuff D; Phogat S; Tang M; Migueles SA; Wu X; Phogat A; Shaw GM; Connors M; Hoxie J; Mascola JR; Wyatt R
J Virol; 2009 Jan; 83(2):1045-59. PubMed ID: 19004942
[TBL] [Abstract][Full Text] [Related]
7. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.
Wibmer CK; Gorman J; Ozorowski G; Bhiman JN; Sheward DJ; Elliott DH; Rouelle J; Smira A; Joyce MG; Ndabambi N; Druz A; Asokan M; Burton DR; Connors M; Abdool Karim SS; Mascola JR; Robinson JE; Ward AB; Williamson C; Kwong PD; Morris L; Moore PL
PLoS Pathog; 2017 Jan; 13(1):e1006074. PubMed ID: 28076415
[TBL] [Abstract][Full Text] [Related]
8. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.
Gray ES; Madiga MC; Hermanus T; Moore PL; Wibmer CK; Tumba NL; Werner L; Mlisana K; Sibeko S; Williamson C; Abdool Karim SS; Morris L;
J Virol; 2011 May; 85(10):4828-40. PubMed ID: 21389135
[TBL] [Abstract][Full Text] [Related]
9. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
Gottardo R; Bailer RT; Korber BT; Gnanakaran S; Phillips J; Shen X; Tomaras GD; Turk E; Imholte G; Eckler L; Wenschuh H; Zerweck J; Greene K; Gao H; Berman PW; Francis D; Sinangil F; Lee C; Nitayaphan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; Robb ML; Michael NL; Kim JH; Zolla-Pazner S; Haynes BF; Mascola JR; Self S; Gilbert P; Montefiori DC
PLoS One; 2013; 8(9):e75665. PubMed ID: 24086607
[TBL] [Abstract][Full Text] [Related]
10. Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site.
Wibmer CK; Gorman J; Anthony CS; Mkhize NN; Druz A; York T; Schmidt SD; Labuschagne P; Louder MK; Bailer RT; Abdool Karim SS; Mascola JR; Williamson C; Moore PL; Kwong PD; Morris L
J Virol; 2016 Nov; 90(22):10220-10235. PubMed ID: 27581986
[TBL] [Abstract][Full Text] [Related]
11. Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.
Longo NS; Sutton MS; Shiakolas AR; Guenaga J; Jarosinski MC; Georgiev IS; McKee K; Bailer RT; Louder MK; O'Dell S; Connors M; Wyatt RT; Mascola JR; Doria-Rose NA
J Virol; 2016 Dec; 90(23):10574-10586. PubMed ID: 27654288
[TBL] [Abstract][Full Text] [Related]
12. Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site.
Crooks ET; Tong T; Chakrabarti B; Narayan K; Georgiev IS; Menis S; Huang X; Kulp D; Osawa K; Muranaka J; Stewart-Jones G; Destefano J; O'Dell S; LaBranche C; Robinson JE; Montefiori DC; McKee K; Du SX; Doria-Rose N; Kwong PD; Mascola JR; Zhu P; Schief WR; Wyatt RT; Whalen RG; Binley JM
PLoS Pathog; 2015 May; 11(5):e1004932. PubMed ID: 26023780
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell Responses.
Ranasinghe S; Soghoian DZ; Lindqvist M; Ghebremichael M; Donaghey F; Carrington M; Seaman MS; Kaufmann DE; Walker BD; Porichis F
J Virol; 2015 Dec; 90(5):2208-20. PubMed ID: 26656715
[TBL] [Abstract][Full Text] [Related]
14. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
15. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
[TBL] [Abstract][Full Text] [Related]
16. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency.
Doria-Rose NA; Bhiman JN; Roark RS; Schramm CA; Gorman J; Chuang GY; Pancera M; Cale EM; Ernandes MJ; Louder MK; Asokan M; Bailer RT; Druz A; Fraschilla IR; Garrett NJ; Jarosinski M; Lynch RM; McKee K; O'Dell S; Pegu A; Schmidt SD; Staupe RP; Sutton MS; Wang K; Wibmer CK; Haynes BF; Abdool-Karim S; Shapiro L; Kwong PD; Moore PL; Morris L; Mascola JR
J Virol; 2016 Jan; 90(1):76-91. PubMed ID: 26468542
[TBL] [Abstract][Full Text] [Related]
17. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.
Davis KL; Gray ES; Moore PL; Decker JM; Salomon A; Montefiori DC; Graham BS; Keefer MC; Pinter A; Morris L; Hahn BH; Shaw GM
Virology; 2009 May; 387(2):414-26. PubMed ID: 19298995
[TBL] [Abstract][Full Text] [Related]
18. Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects.
Sather DN; Stamatatos L
Vaccine; 2010 May; 28 Suppl 2():B8-12. PubMed ID: 20510750
[TBL] [Abstract][Full Text] [Related]
19. Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.
Andrabi R; Kumar R; Bala M; Nair A; Biswas A; Wig N; Kumar P; Pal R; Sinha S; Luthra K
Virol J; 2012 Sep; 9():196. PubMed ID: 22971578
[TBL] [Abstract][Full Text] [Related]
20. Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.
Kumar R; Tuen M; Liu J; Nàdas A; Pan R; Kong X; Hioe CE
Vaccine; 2013 Nov; 31(46):5413-21. PubMed ID: 24051158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
